Saquinavir and rifampicin for tuberculosis and AIDS: New considerations [1]

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 11, 2006, Pages 1302-

  Silva Torres, Thiago ^a   Cavalcanti Rolla, Valeria ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; HUMAN; LETTER; LIVER TOXICITY; PRIORITY JOURNAL; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIBIOTICS, ANTITUBERCULAR; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HUMANS; RIFAMPIN; SAQUINAVIR; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 33750804228     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Gray A, Karim S S A, Gengiah T N. Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings. AIDS 2006; 20: 302-303.
2. La Porte C J L, Colbers E P H, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampicin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553-1560.
3. Rolla V C, Vieira M A S, Ferreira Filho M, et al. Safety efficacy and pharmacokinetics of ritonavir 400 mg and saquinavir 400 mg and rifampicin combined therapy in HIV naive patients with tuberculosis. Rio de Janeiro, Brazil: 3rd IAS Conference on HIV Pathogenesis and Treatment, 2005.
4. F. Hoffmann-La Roche, Ltd. Preliminary Report Study BP18180: effect of multiple dose rifampicin on the steady-state pharmacokinetics of saquinavir combined with low dose ritonavir and vice versa in healthy volunteers. Basel, Switzerland: F. Hoffmann-La Roche, Ltd., March 2005.
5. Ribera E, Azuaje C, Lopes R M, et al. Once daily regimen of saquinavir, ritonavir, didanosine and lamivudine in HIV infected patients with standard tuberculosis therapy. J Acquir Immune Defic Syndr 2005; 40: 317-323.